Philip Morris Competitor Snapshot Altria Group, Inc. (MO) is leaning heavily on its on! nicotine pouch brand to fuel smoke-free growth. In the second quarter of 2025, on! shipments climbed 26.5% year over year to 52.1 million cans. The brand now holds an 8.7% retail share of the U.S. oral tobacco category, and Altria continues to expand visibility through targeted retail campaigns and experiential marketing. Altria is investing to solidify on!'s role as its primary reduced-risk growth driver. Turning Point ...

Core Insights - Altria Group, Inc. is experiencing significant growth in its smoke-free product segment, particularly with its oral nicotine pouch brand, on!, which saw a 26.5% increase in shipments year over year, reaching 52.1 million cans, and capturing an 8.7% share of the total oral tobacco category [1][7] - The nicotine pouch segment now constitutes over half of the oral tobacco category, indicating a shift in consumer preferences away from traditional moist smokeless tobacco [1] - Altria's oral tobacco segment reported a 10.9% increase in adjusted operating income, with margins expanding to 68.7%, despite a 10.2% decline in domestic cigarette shipments [2][3][7] Market Competition - Philip Morris International is aggressively expanding its smoke-free portfolio, with a 17.3% organic growth in smoke-free net revenues, driven by a 26% increase in ZYN U.S. offtake and a 65% rise in international pouch volumes [4] - Turning Point Brands is also making strides in the modern oral nicotine market, with white pouch sales growing nearly 10 times year over year, prompting an increase in full-year guidance to $80-$95 million [5] Stock Performance and Valuation - Altria's shares have increased by 3.8% over the past month, contrasting with a 1.6% decline in the industry [6] - The company is currently trading at a forward price-to-earnings ratio of 11.4X, which is lower than the industry's average of 14.9X [9] - The Zacks Consensus Estimate for Altria's earnings per share for 2025 and 2026 has risen by 2 cents each, now projected at $5.39 and $5.55 respectively [10]

Key Takeaways PM's smoke-free business made up 41% of net revenues and more than 42% of gross profit in Q2 2025.IQOS saw 11.4% global sales growth, with notable market share gains in Japan and Europe.ZYN posted 26% U.S. growth in Q2 and 43% global shipment growth, led by strong U.S. demand.Philip Morris International’s (PM) smoke-free business is gaining scale, and the performance of its flagship products, IQOS and ZYN, is central to this trajectory. In the second quarter of 2025, the company’s smoke-free b ...

Core Insights - Altria Group Inc. reported second-quarter 2025 results with both revenue and earnings exceeding expectations and showing year-over-year growth [1][2][11] Financial Performance - Adjusted earnings per share (EPS) for the second quarter were $1.44, an increase of 8.3% year over year, surpassing the Zacks Consensus Estimate of $1.37 [2][11] - Net revenues totaled $6,102 million, a decline of 1.7% year over year, primarily due to decreased revenues in the smokeable products segment, partially offset by growth in oral tobacco products [3][11] - Revenues net of excise taxes increased by 0.2% to $5,290 million, beating the consensus estimate of $5,190 million [3] Segment Performance - **Smokeable Products**: Net revenues fell 2.5% year over year to $5,357 million, driven by reduced shipment volumes, although higher pricing provided some offset [4][5] - Domestic cigarette shipment volumes decreased by 10.2%, attributed to industry decline and retail share losses, while cigar shipment volumes increased by 3.7% [5] - Adjusted operating companies' income (OCI) in this segment rose 4.2% to $2,947 million, with adjusted OCI margins growing by 2.9 percentage points to 64.5% [6] - **Oral Tobacco Products**: Net revenues increased by 5.9% to $753 million, mainly due to higher pricing, despite a decline in domestic shipment volumes by 1% [7][8] - Adjusted OCI in this segment grew by 10.9%, with adjusted OCI margins increasing by 3.1 percentage points to 68.7% [8] Shareholder Returns and Guidance - The company repurchased 4.7 million shares for $274 million in the second quarter, with $400 million remaining under its $1 billion share repurchase program [10] - Altria paid dividends totaling $1.7 billion in the second quarter [10] - The company narrowed its full-year 2025 adjusted EPS guidance to a range of $5.35 to $5.45, indicating a year-over-year growth of 3% to 5% [11][12]

Altria's Second-Quarter and First-Half 2025 Earnings Conference Call July 30, 2025 1 | ALCS | Q2 2025 | 7.30.25 | For Investor Purposes ONLY Safe Harbor Statement Statements, including earnings guidance, in this presentation that are not reported financial results or other historical information are "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current plans, estimates and expectations, and are not guarantees ...

Core Insights - The tobacco sector presents two main investment options: Altria Group, Inc. and Philip Morris International Inc., each with distinct market strategies and growth trajectories towards a smoke-free future [1][2] Altria Group, Inc. - Altria focuses on the U.S. market, leveraging its Marlboro brand while expanding into alternatives like NJOY and oral nicotine pouches [2] - The company achieved a 10.8% net price realization in smokeable products in Q1 2025, contributing to a 2.7% increase in adjusted operating income [3][9] - Altria's oral nicotine pouch brand, on!, saw an 18% increase in shipments, capturing 8.8% of the oral tobacco category and 17.9% of the nicotine pouch segment [4][9] - Despite setbacks in the e-vapor category, Altria is refining its product pipeline and advocating for regulatory reforms to combat the rise of illicit disposable e-vapor products, which account for over 60% of the U.S. market [5] - The cigarette industry faces challenges, with shipment volumes declining due to macroeconomic pressures and the growth of illegal e-vapor products, impacting low-income smokers [6] Philip Morris International Inc. - Philip Morris is advancing its transformation strategy with a strong smoke-free portfolio, including IQOS, ZYN, and VEEV, and has approximately 41.5 million adult users by Q2 2025 [7][9] - IQOS is the primary driver of growth, with accelerated adoption in key markets supported by commercial initiatives and product innovations [8][10] - The company offers smoke-free products in 97 markets, with nearly half providing multiple product categories, enhancing its global reach [10] - Philip Morris faces challenges such as currency volatility and increasing regulatory risks, particularly regarding nicotine pouch marketing [11] Financial Performance and Valuation - Altria's forward P/E ratio is 10.96, appealing to income-focused investors, while Philip Morris has a higher multiple of 20.12, reflecting its global presence and momentum in smoke-free products [15] - Over the past month, Altria gained 2.1%, while Philip Morris dropped 11.6%, underperforming the S&P 500's 3.4% rise [14] Conclusion - Philip Morris is better positioned for long-term growth with its aggressive pivot towards a smoke-free future and strong global traction, while Altria's focus on domestic stability and pricing strength supports income-focused investors but faces more headwinds [16]

Core Insights - Philip Morris International (PM) raised its 2025 earnings per share (EPS) guidance to $7.43-$7.56, reflecting strong second-quarter performance driven by smoke-free products, indicating a year-over-year growth of 13-15% [1][10] Financial Performance - In Q2 2025, smoke-free net revenues increased by 15.2% year over year, with gross profit for this segment rising over 23%, contributing 41% to total net revenues and 42% to gross profit [2][10] - Adjusted operating income grew by 16.1% in the quarter, outpacing revenue gains, attributed to strong pricing, improved scale efficiencies, and a favorable category mix towards higher-margin smoke-free products [4][10] Product Performance - The multi-category smoke-free platform showed broad-based growth, with IQOS heated tobacco units' adjusted in-market sales rising by 11.4%, supported by global expansion and recovery in European markets [3] - ZYN experienced a significant rebound, with U.S. consumer offtake increasing by 26% in the quarter and 36% in June, driven by better in-store availability and renewed commercial activity [3] Market Strategy - The raised EPS guidance indicates management's confidence in the sustainability of recent smoke-free category growth, suggesting that the multi-category strategy is gaining traction faster than anticipated [5] Competitive Landscape - Altria Group's "on!" nicotine pouch brand saw an 18% increase in shipment volume, while Turning Point Brands reported nearly tenfold growth in modern oral nicotine pouch sales, contributing $22.3 million in revenues [6][7][8] Valuation Metrics - Philip Morris shares have declined by 10.2% in the past month, compared to the industry's decline of 2.2% [9] - The company trades at a forward price-to-earnings ratio of 20.16X, higher than the industry's average of 14.67X [12] - The Zacks Consensus Estimate for PM's earnings implies year-over-year growth of 14.2% for 2025 and 11.9% for 2026 [13]

Core Insights - Altria Group's on! nicotine pouch brand is experiencing significant growth, with shipments increasing by 18% to 39.3 million cans in Q1 2025, contrasting with declines in traditional brands [1][8] - The on! brand now holds an 8.8% share of the total oral tobacco market and a 17.9% share of the nicotine pouch segment, despite rising competition [2][8] - Helix, the manufacturer of on!, has successfully increased brand awareness to over 60% through its "It's On!" campaign, enhancing consumer loyalty [3][8] Market Performance - Philip Morris International's ZYN brand leads the nicotine pouch category, shipping over 200 million cans in Q1 2025, a 63% increase year over year, maintaining over 70% of category value [5] - Turning Point Brands reported a nearly tenfold increase in modern oral revenues to $22.3 million in Q1 2025, raising its full-year nicotine pouch sales forecast to $80-$95 million [6] Valuation and Earnings Estimates - Altria's shares have declined by 2.6% in the past month, while the industry saw a smaller decline of 0.8% [7] - The forward price-to-earnings ratio for Altria is 10.8X, lower than the industry's average of 15.21X [10] - Zacks Consensus Estimates indicate year-over-year earnings growth of 4.9% for 2025 and 3.1% for 2026 [11]

Core Insights - Altria Group, Inc. (MO) has achieved a 21.2% gain over the past six months, outperforming the Zacks Consumer Staples sector's growth of 10.7% and the S&P 500's advance of 6.3% [1] - The stock is trading near its 52-week high of $60.25, just 1.6% below the peak reached on May 7, 2025, indicating strong upward momentum [4] - Altria's strong performance is attributed to robust pricing power in its core combustible tobacco segment, particularly with its flagship brand, Marlboro, which commands a 10.8% net price realization [8][9] Performance Comparison - Altria's stock performance is strong relative to major tobacco players, with Philip Morris International Inc. (PM) surging 51.2%, Turning Point Brands, Inc. (TPB) gaining 28.5%, and British American Tobacco p.l.c. (BTI) increasing by 37% over the same period [3] - The stock's position above key technical benchmarks, including the 50-day and 200-day moving averages, suggests sustained bullish momentum [4][5] Financial Metrics - Altria repurchased 5.7 million shares and paid $1.7 billion in dividends in the first quarter of 2025, reinforcing its commitment to shareholder returns [6][12] - The company's forward 12-month P/E ratio is 11.03, which is attractive compared to the industry average of 15.28, positioning Altria as a compelling value opportunity [13][15] Growth Drivers - The Marlboro brand expanded its share of the premium category to 59.3% in the first quarter, supported by advanced Revenue Growth Management tools [9] - Altria's smoke-free product line, particularly the oral nicotine pouch brand on!, saw an 18% increase in shipments, capturing 8.8% of the oral tobacco category and 17.9% of the nicotine pouch segment [10] - The company is addressing regulatory challenges in the e-vapor category and is committed to refining its product pipeline for future market re-entry [11] Investment Outlook - Altria's combination of strong pricing power, growth in smoke-free products, and a proactive approach to regulatory challenges positions it well for long-term performance [18] - The stock is viewed as a solid opportunity for value and income-focused investors, particularly given its discounted valuation and attractive dividend yield [18]

Core Insights - Altria Group, Inc. is focusing on its oral nicotine pouch brand on! to enhance its presence in the smoke-free category, achieving over 18% shipment growth in Q1 2025 and increasing its market share to 8.8% [1][7] - The brand on! has captured 17.9% of the nicotine pouch segment, reflecting its strength despite competitive pressures and rising prices [1][7] - Strategic investments, particularly the "It's On!" marketing campaign, have significantly boosted consumer awareness, now exceeding 60% [2] Company Performance - Altria's shipment growth for on! is attributed to effective marketing and the upcoming launch of on! PLUS, targeting a key demographic for expansion [2][3] - The company is well-positioned for future growth through disciplined pricing strategies, brand equity, and planned innovations [3] - Altria's stock has gained 1.5% over the past month, contrasting with a 0.2% decline in the industry [6] Peer Comparison - Philip Morris continues to lead the nicotine pouch market with ZYN, reporting a 63% year-over-year increase in shipments, reaching over 200 million cans in Q1 2025 [4] - Turning Point Brands is also gaining traction with its modern oral products, forecasting nearly 10x year-over-year growth and expanding its sales force [5] Valuation and Earnings Estimates - Altria trades at a forward price-to-earnings ratio of 10.84X, below the industry average of 15.11X [8] - The Zacks Consensus Estimate indicates year-over-year earnings growth of 4.9% for 2025 and 3.3% for 2026 [9]